Change over period: —
NSE · SMSPHARMA
SMS PHARMACE
-9.3% from the 52-week high · +75.6% above the low
SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 1,095 full-time employees. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic and others. The firm products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel and lamotrigine. The firm has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
The short version. SMS PHARMACE reported revenue of ₹316 crore for Sep 2026, up 30.6% from a year earlier. Net profit was ₹40 crore (up 60.0% year on year). Return on equity was 13.0% in Mar 2026. Promoter holding was 68.07% in Sep 2026, up 3.40 points over 8 quarters.
1 · The price
How has the stock traded?
SMS PHARMACE trades 9.3% below its 52-week high and 75.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹316 cr.
Sep 2026 net profit of ₹40 cr.
2.2 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 316 | 207 | 238 | 210 | 242 | 196 | 248 | 173 |
| Net profit | 40 | 21 | 33 | 23 | 25 | 20 | 20 | 18 |
| Net margin % | 12.6 | 10.1 | 13.9 | 11.2 | 10.4 | 10.5 | 8.2 | 10.5 |
| EPS (₹) | 4.26 | 2.23 | 3.52 | 2.51 | 2.7 | 2.19 | 2.29 | 2.16 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 887 | 783 | 709 | 522 | 520 | 563 | 412 | 465 |
| Net profit | 102 | 69 | 50 | -7 | 62 | 63 | 33 | 53 |
| Net margin % | 11.5 | 8.8 | 7.0 | -1.4 | 12.0 | 11.1 | 7.9 | 11.5 |
| EPS (₹) | 10.9 | 7.8 | 5.89 | -0.83 | 7.35 | 7.39 | 3.86 | 6.31 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 13.0% in Mar 2026; debt to equity is 0.46.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 13.0 | 10.8 | 9.3 | -1.5 |
| Return on capital % | 13.8 | 13.4 | 12.8 | 4.4 |
| EBITDA margin % | 20.1 | 18.4 | 17.0 | 11.3 |
| Net margin % | 11.4 | 8.8 | 7.0 | -1.3 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 19.3% | 9.6% |
| Profit CAGR | — | 10.3% |
4 · The owners
Who holds it, and are they adding?
Up 3.4 pts over 8 quarters.
Up 0.87 pts over 8 quarters.
Down 2.35 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 64.67 | 66.26 | 68.07 | 68.07 | 68.07 | 68.07 | 68.07 | 68.07 | +3.4 |
| FII | 0.31 | 0.08 | 0.17 | 0.28 | 0.04 | 0.31 | 0.65 | 1.18 | +0.87 |
| DII | 2.55 | 2.43 | 2.88 | 2.88 | 3.21 | 3.02 | 2.83 | 0.2 | -2.35 |
| Public | 32.47 | 31.22 | 28.89 | 28.78 | 28.69 | 28.6 | 28.45 | 30.56 | -1.91 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.09% of NAV
- Bandhan BSE Healthcare Index Fund0.09% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SMS PHARMACE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about SMS PHARMACE
What is the SMS PHARMACE share price?
SMS PHARMACE (SMSPHARMA) last closed at ₹481.35, up 0.95% on the day. Its 52-week range is ₹271.55 to ₹525.50.
What is the market cap of SMS PHARMACE?
SMS PHARMACE has a market capitalisation of about ₹4,472 crore. Its price-to-earnings ratio is 38.1.
How are SMS PHARMACE's latest results?
SMS PHARMACE reported revenue of ₹316 crore for Sep 2026, up 30.6% from a year earlier. Net profit was ₹40 crore (up 60.0% year on year). Return on equity was 13.0% in Mar 2026. Promoter holding was 68.07% in Sep 2026, up 3.40 points over 8 quarters.
Who owns SMS PHARMACE?
As of Sep 2026, shareholding was: Promoter 68.07%, FII 1.18%, DII 0.2%, Public 30.56%.
How many mutual funds hold SMS PHARMACE?
2 mutual fund schemes held SMS PHARMACE in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 22 Sep 2025 · Final Dividend - Rs. 0.4
- 23 Sep 2024 · Final Dividend - Rs. 0.4
- 22 Sep 2023 · Final Dividend - Rs. 0.3
- 22 Sep 2022 · Final Dividend - Rs. 0.3
- 22 Sep 2021 · Final Dividend - Rs. 0.3
- 26 Mar 2020 · Interim Dividend - Rs. 0.25
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.